During the past decade, Alzheimer Disease Center conducted 2 clinical trials. In the 10-year time frame, 2 clinical trials started and 1 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Alzheimer Disease Center" #1 collaborator was "National Institute on Aging (NIA)" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 1 trials.

According to Clinical.Site data, the most researched conditions in "Alzheimer Disease Center" are "Dementia" (1 trials) and "Dementia-related Psychosis" (1 trials). Many other conditions were trialed in "Alzheimer Disease Center" in a lesser frequency.

Most popular intervention types in "Alzheimer Disease Center" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (2 trials), "Escitalopram" (1 trials), "Pimavanserin 20 mg" (1 trials) and "Pimavanserin 34 mg" (1 trials). Other intervention names were less common.

The vast majority of trials in "Alzheimer Disease Center" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Alzheimer Disease Center". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Alzheimer Disease Center, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Alzheimer Disease Center, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".